The UK and US have announced a important trade agreement that will maintain no tariffs on UK drug products being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to raise spending on medicines through the National Health Service (NHS). This move ensures that import taxes on these vital goods will stay at zero for a duration of the next three years.
This development is in response to previous warnings to dramatically increase tariffs on patented drug products, with increases discussed up to double the cost.
"This agreement with the United Kingdom reinforces the worldwide climate for innovative medicines and establishes long-overdue fairness to U.S.–U.K. medicine commerce," a statement said.
Commercial Significance
Pharmaceuticals constitute one of the UK's biggest exports to the America, which is by far the biggest market for leading British pharmaceutical firms.
Statistics indicate that in the 12 months to the end of last September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This amount made up 17.4% of British export trade in that period.
"This deal secures work, increases investment and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister remarked.
Specific British Pledges
The agreement includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to double overall public funding on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. In the past, refunds exceeded 20%.
Recent Tensions
This agreement comes amid a long-running row between the drug companies and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by assertions that American patients were paying significantly more for the equivalent treatments than consumers in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been halted or cancelled, while major expansions have been announced toward US facilities.
The Science Minister acknowledged that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
